Head to Head Contrast: Diageo (NYSE:DEO) & Arcadia Biosciences (NASDAQ:RKDA)

Arcadia Biosciences (NASDAQ:RKDA) and Diageo (NYSE:DEO) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Risk & Volatility

Arcadia Biosciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Diageo has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 9.0% of Diageo shares are held by institutional investors. 8.2% of Arcadia Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Arcadia Biosciences and Diageo, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1	0	0	0	1.00
Diageo	2	4	6	0	2.33

Diageo has a consensus target price of $106.25, suggesting a potential upside of 10.43%. Given Diageo’s stronger consensus rating and higher probable upside, analysts plainly believe Diageo is more favorable than Arcadia Biosciences.

Profitability

This table compares Arcadia Biosciences and Diageo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-195.94%	-113.73%	-68.47%
Diageo	N/A	N/A	N/A

Valuation & Earnings

This table compares Arcadia Biosciences and Diageo”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86 million	0.35	-$2.34 million	($5.73)	-0.12
Diageo	$19.64 billion	2.73	$2.35 billion	N/A	N/A

Diageo has higher revenue and earnings than Arcadia Biosciences.

Summary

Diageo beats Arcadia Biosciences on 9 of the 12 factors compared between the two stocks.

About Arcadia Biosciences

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

About Diageo

Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products. The company provides its products under the Johnnie Walker, Crown Royal, J&B, Buchanan’s, Smirnoff, Cîroc, Ketel One, Captain Morgan, Baileys, Don Julio, Casamigos, Tanqueray, Guinness, Shui Jing Fang, Yenì, McDowell’s, Don Papa, Aviation American, Seagram, Seagram’s 7 Crown, Zacapa, Black Dog, Black & White, Signature, Royal Challenge, Godawan, Antiquity, Gordon’s, Old Parr, Windsor, Bundaberg, Ypióca, Bulleit, and Bell’s brand names. It operates in the United States, the United Kingdom, Türkiye, Australia, Korea, India, Greater China, Brazil, Mexico, South Africa, Nigeria, and internationally. The company was incorporated in 1886 and is headquartered in London, the United Kingdom.